UBS downgraded MorphoSys to Neutral from Buy with a price target of EUR 68, up from EUR 47. The analyst cites the pending takeover by Novartis for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOR:
- MorphoSys downgraded to Market Perform from Outperform at JMP Securities
- MorphoSys tells Bloomberg STAT story ‘factually wrong’
- Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says
- M & A News: Novartis (NYSE:NVS) to Acquire MorphoSys in $2.9B Deal
- MorphoSys upgraded to Neutral from Sell at Citi